Please login to the form below

Not currently logged in
Email:
Password:

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

Morris Birnbaum PfizerPfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into cardiovascular and metabolic diseases.

Dr Birnbaum most recently served as Willard Ware professor of diabetes and metabolic diseases and associate dean for biomedical core resources at the Perelman School of Medicine at the University of Pennsylvania.

In his academic career he has authored more than 200 scientific papers and has built an expertise in intracellular metabolism - a key component to understanding diabetes and its relationship to cardiovascular disease.

“His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients,” said Dr Rod MacKenzie, group senior VP and head of PharmaTherapeutics R&D.

Pfizer's interests in the area include a collaboration with Merck & Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes. The company is also developing bococizumab for hypercholesterolemia.

5th June 2014

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...